核心观点 - MetaVia与Syntekabio达成合作 利用后者AI平台DeepMatcher®扩大GPR119激动剂DA-1241的适应症范围 通过虚拟筛选1700多个蛋白靶点寻找新适应症[1][3] - DA-1241在109人参与的IIa期试验中展现出良好安全性 兼具肝脏保护和血糖调节作用 针对代谢功能障碍相关脂肪性肝炎(MASH)患者[2][4] 合作细节 - Syntekabio将提供化合物-蛋白质相互作用预测平台 帮助优化DA-1241的治疗特性 确保靶向特异性并减少脱靶风险[3] - 合作预计2025年内获得初步成果 目标挖掘该口服候选药物在未满足医疗需求领域的潜力[3] 药物特性 - DA-1241是新型GPR119激动剂 通过刺激肠道释放GLP-1 GIP PYY等肽类 影响糖脂代谢和体重[4] - 临床前研究显示其对肝脏炎症 纤维化 脂肪变性有改善作用 并在IIa期试验中证实直接肝脏作用[4][6] 公司背景 - MetaVia专注于心血管代谢疾病领域 管线包括肥胖治疗药物DA-1726(OXM类似物)和MASH药物DA-1241[6] - Syntekabio是AI驱动药物发现公司 拥有超级计算机云平台 可快速生成从靶点到IND阶段的候选化合物[5]

DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) (“374Water”) (the “Company”), a global leader in organic waste destruction technology and services for the municipal, federal, and industrial markets, will hold a conference call on Tuesday, August 12, 2025 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2025. A press release detailing these results will be issued prior to the call. 374Water CEO Chris Gannon and CFO Russell Kline will host the ...

GEORGE TOWN, Cayman Islands, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, will hold a conference call on Tuesday, August 12, 2025 at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30, 2025. The financial results will be issued in a press release prior to the call. Consolidated Water management will host the call, followed by a questio ...

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure:I/we have a beneficial long position in the shares of MO either th ...

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days Initiated two registrational studies for Developmental and Epileptic Encephalopathies (DEEs) programs: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen Relutrigine granted U.S. FDA Breakthrough Therapy Designation for the treatment of seizures asso ...

Sydney, Australia and New York, NY, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Integrated Wellness Acquisition Corp (OTC: WELNF) (“WEL”), a publicly traded special purpose acquisition company, and Btab Ecommerce Group, Inc., (OTC: BBTT) (“Btab”), a global e-commerce and digital supply chain solutions provider, today jointly announced the public filing of a registration statement on Form S-4 by IWAC Holding Company Inc., a newly created holding company organized under the laws of Delaware (“Pubco”), with the U.S. Sec ...

PLEASANTON, Calif., Aug. 4, 2025 /PRNewswire/ -- Workday, Inc. (NASDAQ: WDAY), the AI platform for managing people, money, and agents, today announced that it will host its financial analyst day on Tuesday, September 16, 2025 in San Francisco at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The event will take place during Workday Rising, the company's annual flagship conference for finance, HR, and IT professionals.A live webcast of the event will be available on the Workday Investor Relations site. The ...

AKRON, Ohio, Aug. 4, 2025 /PRNewswire/ -- The Goodyear Tire & Rubber Company (NASDAQ: GT) will report second quarter 2025 financial results after market close on Thursday, August 7, followed by an investor conference call at 8:30 a.m. Eastern time on Friday, August 8.The Company will publish its results on August 7, in the form of an Earnings Release and an additional presentation on its investor relations website: http://investor.goodyear.com. The following morning, the Company will host an investor call.T ...

公司临床进展 - 公司在2025年取得多项临床开发里程碑 包括持续推进两项肺癌临床试验的患者治疗 [1] - 公司发布股东信函和业务更新 总结近期在肿瘤学和糖尿病项目上的成就 并概述2025年及未来的关键里程碑 [1] - 公司总裁兼CEO表示 通过精简聚焦的战略 在推进临床开发项目的同时为整个公司创造价值 [2] 技术平台与产品管线 - 公司专注于开发针对癌症和糖尿病患者的基因疗法 其技术旨在通过递送疾病对抗基因 为目前治疗选择有限的大患者群体提供新疗法 [3] - 肿瘤学项目采用Oncoprex®非病毒递送系统 通过脂质纳米颗粒封装基因表达质粒 静脉注射后 肿瘤细胞摄取并表达肿瘤抑制蛋白 [3] - 主导产品Reqorsa®基因疗法正在两项临床试验中评估治疗非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC)的潜力 两项肺癌项目均获FDA快速通道认定 SCLC项目还获得孤儿药资格 [3] 糖尿病基因疗法 - 糖尿病基因疗法采用新型输注工艺 使用AAV载体将Pdx1和MafA基因递送至胰腺 [3] - 在1型糖尿病模型中 GPX-002将胰腺α细胞转化为功能性β样细胞 这些细胞能产生胰岛素但可能足够区别于β细胞以逃避免疫系统 [3] - 在2型糖尿病中 GPX-002被认为可 rejuvenate 和 replenish 耗竭的β细胞 [3] 合作与投资者关系 - 公司与世界一流机构和合作者共同开发候选药物 以推进基因治疗管线 [3] - 鼓励投资者和股东通过公司网站注册电子邮件提醒 并在Twitter Facebook和LinkedIn上关注公司 以获取新闻稿和行业更新 [4]

公司公告 - Vivakor Inc将于2025年9月11日9:00 CST在德克萨斯州达拉斯举行年度股东大会 会议仅限线下参与 [1] - 股东需在2025年8月13日前完成登记 可通过现场或代理方式投票 如需协助可联系公司邮箱info@vivakorcom [2] 公司业务 - Vivakor是综合性可持续能源运输、储存、再利用及修复服务提供商 运营美国本土最大规模的油田卡车运输车队之一 [3] - 公司核心战略为开发、收购和运营能源领域资产、物业及技术 其综合设施提供原油收集、储存、运输、再利用及修复服务 均基于长期合约 [3] - 油田废弃物修复设施专注于石油副产品及油田废弃物的回收、再利用与处置 [3] 投资者联系 - 投资者可通过电话949-281-2606或邮箱info@vivakorcom联系公司 [6]